The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

被引:24
|
作者
Anonychuk, Andrea [1 ,2 ,3 ]
Woo, Gloria [4 ]
Vyse, Andrew [1 ]
Demarteau, Nadia [1 ]
Tricco, Andrea C. [5 ]
机构
[1] GlaxoSmithKline Vaccines, Wavre, Belgium
[2] Abbott Labs, Div Diagnost, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Div Diagnost, Mississauga, ON L5N 3R3, Canada
[4] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
关键词
NEISSERIA-MENINGITIDIS; CONJUGATE VACCINE; UNITED-STATES; SEROGROUP; IMMUNOGENICITY; POLYSACCHARIDE; SAFETY; W-135; INFECTION; ENGLAND;
D O I
10.1007/s40273-013-0057-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Invasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases. Objective To systematically review the literature on the costs and public health burden associated with IMD outbreaks. Methods Studies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community). Results Sixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222. Conclusion IMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
引用
收藏
页码:563 / 576
页数:14
相关论文
共 50 条
  • [31] Burden of Childhood Injuries in India and Possible Public Health Interventions: A Systematic Review
    Kumar, Mohan
    Pathak, Vineet Kumar
    Tripathi, Saparya
    Upadhyay, Anita
    Singh, Vivek V.
    Lahariya, Chandrakant
    INDIAN JOURNAL OF COMMUNITY MEDICINE, 2023, 48 (05) : 648 - +
  • [32] Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database
    Weil-Olivier, Catherine
    Taha, Muhamed-Kheir
    Emery, Corinne
    Bouee, Stephane
    Beck, Ekkehard
    Aris, Emmanuel
    Loncle-Provot, Veronique
    Nachbaur, Gaelle
    Pribil, Celine
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (03) : 1607 - 1623
  • [33] Meningococcal burden of disease in Argentina: 10 years epidemiologic review
    Neyro, Silvina
    Uruena, Analia
    Efron, Adriana
    Rancano, Carolina
    Pannunzio, Maria E.
    Seoane, Maria B.
    Gomez, Jorge A.
    Giglio, Norberto
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [34] Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis
    Campbell, Helen
    Borrow, Ray
    Arumugam, Chitra
    Ramsay, Mary
    Ladhani, Shamez N.
    JOURNAL OF INFECTION, 2019, 78 (04) : 326 - 327
  • [35] Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database
    Weil-Olivier, Catherine
    Taha, Muhamed-Kheir
    Bouee, Stephane
    Emery, Corinne
    Loncle-Provot, Veronique
    Nachbaur, Gaelle
    Beck, Ekkehard
    Pribil, Celine
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [36] Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada
    Rampakakis, Emmanouil
    Vaillancourt, Julie
    Mursleen, Sara
    Sampalis, John S.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (03) : 253 - 257
  • [37] Management of meningococcal outbreaks: are we using the same language? Comparison of the public health policies between high-income countries with low incidence of meningococcal disease
    Burmaz, Tea
    Guicciardi, Stefano
    Selle, Vittorio
    Lopalco, Pier Luigi
    Baldo, Vincenzo
    Fantini, Maria Pia
    EXPERT REVIEW OF VACCINES, 2019, 18 (05) : 559 - 574
  • [38] Global Burden of Neonatal Invasive Pneumococcal Disease A Systematic Review and Meta-analysis
    Billings, Monisha E.
    Deloria-Knoll, Maria
    O'Brien, Katherine L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (02) : 172 - 179
  • [39] Meningococcal disease burden and transmission in crowded settings and mass gatherings other than Hajj/Umrah: A systematic review
    Badandah, Al-Mamoon
    Rashid, Harunor
    Khatami, Ameneh
    Booy, Robert
    VACCINE, 2018, 36 (31) : 4593 - 4602
  • [40] An Update on Fungal Disease Outbreaks of Public Health Concern
    Smith, Dallas J.
    Gold, Jeremy A. W.
    Williams, Samantha L.
    Hennessee, Ian
    Jones, Sophie
    Chiller, Tom
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2025, 39 (01) : 23 - 40